A peripheral system disease—Pulmonary hypertension - 29/05/24
, Qidi Ai b, ⁎
, Shasha Liu a, ⁎ 
Abstract |
Pulmonary hypertension (PH) is a cardiovascular disorder characterized by substantial morbidity and mortality rates. It is a chronic condition characterized by intricate pathogenesis and uncontrollable factors. We summarized the pathological effects of estrogen, genetics, neuroinflammation, intestinal microbiota, metabolic reorganization, and histone modification on PH. PH is not only a pulmonary vascular disease, but also a systemic disease. The findings emphasize that the onset of PH is not exclusively confined to the pulmonary vasculature, consequently necessitating treatment approaches that extend beyond targeting pulmonary blood vessels. Hence, the research on the pathological mechanism of PH is not limited to target organs such as pulmonary vessels, but also focuses on exploring other fields (such as estrogen, genetics, neuroinflammation, intestinal microbiota, metabolic reorganization, and histone modification).
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Abbreviations : PH, NO, ROS, EnMT, WHO, MPAP, PED-5, ASIV, CTEPH, PVOD/PCH, PAH, PASMCs, Endothelial cells, VSMCs, IL, MCP, TNF, MCT, ICAM-1, ELAM-1, SOD, MDA, EIF2, MAP1LC3B, HIF-2α, LVECs, CSQ2, NIH, OVX, ERα, ERβ, GPR30, 16αOHE1, BMPR2, FDA, CAI, SuHx, SOCE, ENOS, CGMP, HPASMCs, Hes-5, IGFR1, ET-1, TGF-β, FGF-2, VEGF-2, HDCA
Keywords : Pulmonary hypertension, Mechanism, Treatment, Systemic disease
Plan
Vol 175
Article 116787- juin 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
